Keonhee Kim's questions to Teva Pharmaceutical Industries Ltd (TEVA) leadership • Q2 2025
Question
Keonhee Kim of Morningstar asked about the commercial progress of the Selarsdi (ustekinumab biosimilar) rollout and whether its market dynamics are expected to be similar to the slower uptake seen with Humira biosimilars.
Answer
President and CEO Richard Francis explained that every biosimilar launch is unique and that Teva's agile U.S. team is executing well. He emphasized that Selarsdi is part of a broader portfolio play, which gives them confidence in their goal to double biosimilar revenue by 2027 without relying on any single product to be a 'superstar'.